The U.S. Food and Drug Administration approved Moderna's mFlusiva, the first mRNA-based seasonal flu vaccine authorized for use in the United States [1].
This approval represents a shift in how seasonal influenza is managed by utilizing the same technology used in COVID-19 vaccines. The move could allow for faster production cycles and potentially higher efficacy compared to traditional egg-based manufacturing methods.
The vaccine, known as mRNA-1010, is specifically approved for adults 50 years and older [2]. This includes two distinct age brackets: those between 50 and 65, and those 65 and older [2]. The FDA granted the approval on Wednesday, March 20, 2024 [3].
Moderna developed the vaccine to provide a more effective and rapidly producible option for flu prevention. The target demographic of older adults was prioritized after the company faced earlier regulatory questioning regarding the vaccine's review [4].
Unlike traditional flu shots, which often rely on growing virus strains in chicken eggs, mRNA vaccines use a genetic sequence to teach the body how to recognize the virus. This process allows scientists to update the vaccine's formula more quickly as the virus mutates each season [4].
The approval follows a period of scrutiny from regulators. The FDA had previously issued a rare refusal to review the vaccine before the company adjusted its approach and target population [4]. The final authorization confirms the safety and efficacy of the shot for the specified adult populations [1].
“The U.S. Food and Drug Administration approved Moderna's mFlusiva, the first mRNA-based seasonal flu vaccine authorized for use in the United States.”
The authorization of mFlusiva signals a broader transition toward genomic medicine in public health. By moving away from egg-based production, the U.S. health system can reduce the 'mismatch' between the vaccine strain and the circulating virus. This is particularly critical for adults over 50, who are more susceptible to severe flu complications, and establishes a regulatory precedent for other mRNA respiratory vaccines.
